Third-party sellers on Amazon's marketplace are significantly outspending established brands on bottom-of-funnel advertising, ...
FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...